GlassScriptPhysician profile
David J Scholl
NPI 1003811886
$3,772.23
in general payments reported to CMS, 2019-2025
35 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.84 · 2022: $334 · 2023: $774 · 2024: $1,138 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.53 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $293.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,427.44 | 2023-2025 | |
| Pfizer INC. | $466.20 | 2021-2025 | |
| Janssen Biotech, INC. | $241.77 | 2022-2025 | Erleada, Tecvayli, Darzalex |
| Incyte Corporation | $140.40 | 2021-2024 | Jakafi |
| Daiichi Sankyo INC. | $126.27 | 2022-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $124.21 | 2022-2025 | Keytruda |
| Eisai INC. | $100.42 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.97 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $86.37 | 2023-2025 | Opdivo |
| Seagen INC. | $81.76 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Lilly USA, LLC | $74.93 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals LP | $74.76 | 2024-2025 | Lynparza |
| Exelixis INC. | $65.10 | 2023-2025 | Cabometyx |
| Gilead Sciences, INC. | $63.67 | 2022-2024 | |
| Glaxosmithkline, LLC. | $61.57 | 2023-2025 | Ojjaara, Shingrix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56.02 | 2025 | |
| Stemline Therapeutics INC. | $52.18 | 2023-2024 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $47.08 | 2022 | |
| Genentech USA, INC. | $46.01 | 2024-2025 | Alecensa, Tecentriq, Rozlytrek |
| Caris Mpi, INC. | $35.48 | 2025 | Mi Cancer Seek |
| Regeneron Healthcare Solutions, INC. | $28.80 | 2022 | |
| Geron Corporation | $26.92 | 2024 | Rytelo |
| Deciphera Pharmaceuticals INC. | $25.24 | 2024 | Tgct, Qinlock |
| Genentech, INC. | $23.54 | 2024 | Phesgo, Tecentriq Hybreza |
| Beigene USA, INC. | $22.53 | 2024 | Brukinsa |
| Puma Biotechnology, INC. | $22.38 | 2025 | |
| Sobi, INC | $22.15 | 2022 | |
| Beone Medicines USA, INC. | $21.71 | 2025 | Brukinsa |
| Genzyme Corporation | $20.96 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.45 | 2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $17.60 | 2024 | Onivyde |
| Sumitomo Pharma America, INC. | $16.06 | 2023 | Orgovyx |
| Amgen INC. | $14.65 | 2023 | Lumakras |
| Array Biopharma INC | $12.43 | 2023 | Braftovi, Mektovi |
| Celgene Corporation | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scholl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.